DDInter704 DDInter833
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Everolimus {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Everolimus {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Glycerol phenylbutyrate
Everolimus {u} (Compound) resembles {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Everolimus (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Everolimus (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Alverine (Compound) and Alverine (Compound) resembles Glycerol phenylbutyrate (Compound)
Everolimus (Compound) resembles Tacrolimus (Compound) and Tacrolimus (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)